Digenio A, et al. - In overweight patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea therapy, the authors assessed safety and efficacy of IONIS-PTP-1B_Rx (a second-generation 2'-O-methoxyethyl antisense inhibitor of protein tyrosine phosphatase 1B) as add-on therapy. Prolonged reductions in HbA_1c, improvement in medium-term glycemic parameters, reduction in leptin, and an increase in adiponectin levels were achieved due to IONIS-PTP-1B_Rx treatment for 26 weeks when compared with placebo. This treatment also led to a distinct body weight reducing effect.